The present invention relates to formulation comprising (i) at least one virus-based material, (ii) at least one polymer selected from the group of polyvinylpyrrolidone and copovidone, and mixtures thereof, (iii) at least one disaccharide, (iv) arginine and glutamate, (v) at least one phosphate salt and at least one pharmaceutically acceptable monovalent salt and, optionally (vi) a pharmaceutical acceptable buffer. Such a formulation is particularly suitable for freeze-drying and addresses problems associated with storage of virus-containing formulations, such as breakdown due to thermal degradation. The present invention also relates to the corresponding dry product, as well as its preparation process. The present invention also relates to a reconstituted material comprising said dry product, which can be administered to a patient in need thereof. Such formulation and reconstituted material are useful as vaccines, preferably for the treatment and/or the prevention of cancers, infectious diseases and/or autoimmune disorders.
